Adherence to long-term therapies in cystic fibrosis: a French cross-sectional study linking prescribing, dispensing, and hospitalization data

Q: Which patient groups were included?

The study included 228 non-transplanted patients followed in two adult and two pediatric cystic fibrosis centers in France during 2015.

Q: What did the results show about adherence patterns?

Medication chronicity increased with age, while cCMA differed significantly across age groups and pharmaceutical forms. Adherence was suboptimal and varied substantially between groups and between oral and inhaled medications.

Oct 3, 2026

Uploaded by pop out

Adherence to medication is critical for cystic fibrosis management, yet adherence patterns and their determinants remain insufficiently characterized. This cross-sectional study evaluated medication adherence over 12 months in adults and children followed in four French regional cystic fibrosis centers, using continuous medication availability derived from French National Health Insurance claims and accounting for dose adjustments and hospitalizations. A total of 228 non-transplanted patients were analyzed, showing suboptimal, age- and form-dependent adherence.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages14

Reading Time35 min

AccessFree to download

Background

Objective

Methods

Results

Conclusion

Patient Preference and Adherence Dovepress open access to scientiﬁc and medical research Open Access Full Text Article ORIGINAL RE SE ARCH Patient Preference and Adherence downloaded from [https://www.dovepress.com/](https://www.dovepress.com/) For personal use only. Adherence to long-term therapies in cystic ﬁbrosis: a French cross-sectional study linking prescribing, dispensing, and hospitalization data This article was published in the following Dove Press journal: Patient Preference and Adherence Héloïse Rouzé 1 , 2 Marie Viprey 1 , 2 Samuel Allemann2 Alexandra L Dima 2 Pascal Caillet 3 Angélique Denis 1 Stéphanie Poupon-Bourdy 1 Boubou Camara4 Catherine Llerena 5 Philippe Reix6 Isabelle Durieu2 , 7 Quitterie Reynaud2 , 7 Sandrine Touzet 1 , 2 1 Public Health Department, Hospices Civils de Lyon, Lyon, France; 2HESPER Lab-EA 7425, Université de LyonUniversité Claude Bernard Lyon 1, Lyon, France; 3Department of Clinical Pharmacology, CHU de Nantes, Nantes, France; 4Pulmonary Department, Adult CF Center, CHU de Grenoble, Grenoble, France; 5Pediatric Pulmonology Department, Pediatric CF Center, CHU de Grenoble, Grenoble, France; 6Pediatric Pulmonology Department, Pediatric CF Center, Hôpital FemmeMère-Enfant, Hospices Civils de Lyon, Lyon, France; 7Department of Internal Medicine, Adult Cystic Fibrosis Care Center, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France Correspondence: Héloïse Rouzé Hospices Civils de Lyon, Pôle de Santé Publique, Bâtiment A, 6ème étage, 162 Avenue Lacassagne 69003 Lyon, France Tel +33 47 211 5132 Email [heloise.rouze@chu-lyon.fr](heloise.rouze@chu-lyon.fr) Background: Cystic ﬁbrosis (CF) is a life-shortening genetic condition that usually affects several organs and involves signiﬁcant treatment burden. Adherence to medication is important for successful CF management. Objective: To describe medication adherence according to age, therapeutic class, and pharmaceutical form in adults and children followed in four regional CF centers in France. Methods: We conducted a cross-sectional study with non-transplanted patients followed in two adult and two pediatric centers during 2015 who were covered by the French National Health Insurance (NHI) . Sociodemographic, clinical, hospitalization, and prescription data were collected from patient medical records. Medication dispensations were extracted from the regional French NHI database. Adherence was calculated over 12 months using continuous medication availability (CMA) accounting for dose adjustments and hospitalizations. Drug-speciﬁc CMA was computed in R with the AdhereR package for each medication prescribed more than 3 months, which was averaged to obtain a composite CMA score (cCMA) for all treatments and per therapeutic class as well as pharmaceutical form for each patient. Results: A total of 228 patients were included. The number of chronic medications increased with age (r=0.50, p<0.001): a median of 7 medications per patient were prescribed. The mean±SD cCMA was signiﬁcantly different between age groups (p=0.0098): it was 0.71 ±0.20 for the 0–5 years age group, 0.73±0.16 for 6–11 years, 0.64±0.17 for 12–17 years, 0.57 ±0.23 for 18–25 years, and 0.65±0.20 for the over 25 years age group. cCMA varied signiﬁcantly according to pharmaceutical forms: the mean±SD cCMA was 0.70±0.21 for oral medications and 0.54±0.28 for inhaled medications (p<0.001) . Conclusion: This study suggests that adherence to medication regimens in CF patients remains suboptimal and varies substantially between age groups and pharmaceutical forms. These variations in adherence should be considered when developing effective strategies to improve adherence. Keywords: cystic ﬁbrosis, chronic treatment, medication adherence, administrative claims data, prescription data Background Cystic ﬁbrosis (CF) is a life-shortening inherited disease that usually affects several organs, although pulmonary disease predominately con

FAQs

How was medication adherence measured in this study?

Adherence was calculated over 12 months using continuous medication availability (CMA), accounting for dose adjustments and hospitalizations. Drug-specific CMA was computed and averaged into a composite CMA score (cCMA).

Which patient groups were included?

The study included 228 non-transplanted patients followed in two adult and two pediatric cystic fibrosis centers in France during 2015.

What did the results show about adherence patterns?

Medication chronicity increased with age, while cCMA differed significantly across age groups and pharmaceutical forms. Adherence was suboptimal and varied substantially between groups and between oral and inhaled medications.

Oct 3, 2026

Uploaded by pop out